Showing 478 news articles about New & experimental hepatitis C treatment

Filters Content type: Editors' picks Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C

Editor's pick
Gilled press relase
27 May 2016
New & experimental hepatitis C treatment

Fair Pricing Coalition Recognizes Merck’s Lower Price for Curative Hepatitis C Treatment, Calls for Manufacturers to Reduce Excessive Prices and Increase Patient Assistance

Editor's pick
Fair Pricing Coalition
8 February 2016
New & experimental hepatitis C treatment

U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

Editor's pick
Bristol-Myers Squibb press release
8 February 2016
Pharmaceutical industry

Merck Throws a Wrench in Drug Pricing

Editor's pick
Bloomberg
1 February 2016
New & experimental hepatitis C treatment

Zepatier for hepatitis C approved in Canada

Editor's pick
CATIE
1 February 2016
New & experimental hepatitis C treatment

Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults

Editor's pick
Merck press release
29 January 2016
New & experimental hepatitis C treatment

The 2016 Hepatitis C Drug Approval Outlook

Editor's pick
Poz
18 January 2016
New & experimental hepatitis C treatment

AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen

Editor's pick
AbbVie press release
11 January 2016
New & experimental hepatitis C treatment

Mylan Launches Generic Harvoni® (Ledipasvir/Sofosbuvir) Under the Brand Name MyHep LVIR™ in India

Editor's pick
Mylan press release
8 January 2016
New & experimental hepatitis C treatment

Inside the hepatitis C virus is a promising antiviral

Editor's pick
Medical Xpress
6 January 2016
New & experimental hepatitis C treatment

Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chronic Hepatitis C Infection

Editor's pick
Gilead press release
5 January 2016
New & experimental hepatitis C treatment

AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK®

Editor's pick
AbbVie press release
2 December 2015
New & experimental hepatitis C treatment

Study suggests unprecedented 3-week hepatitis C cure

Editor's pick
Science
2 November 2015
New & experimental hepatitis C treatment

Gilead Seeks FDA Approval for Hep C Treatment for All Genotypes

Editor's pick
AIDSMeds
2 November 2015
New & experimental hepatitis C treatment

'Dallas Buyers' Club' for Hep C treatments under investigation

Editor's pick
Sydney Morning Herald
22 October 2015
New & experimental hepatitis C treatment

NICE Recommends Daklinza (daclatasvir) for Treatment of Certain Patients with Chronic Hepatitis C Genotypes 1, 3 and 4

Editor's pick
Bristol-Myers Squibb press release
16 October 2015
New & experimental hepatitis C treatment

U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs

Editor's pick
Bristol-Myers Squibb
7 October 2015
New & experimental hepatitis C treatment

Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes

Editor's pick
Gilead press release
21 September 2015
New & experimental hepatitis C treatment

Achillion Reports 100% SVR12 From Second Cohort of Patients in the Previously-Completed Six Week Phase 2 Trial Evaluating Odalasvir (ACH-3102) and Sofosbuvir for Genotype 1 HCV ("Proxy Study")

Editor's pick
Achillion press release
18 September 2015
New & experimental hepatitis C treatment

Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission

Editor's pick
Bristol-Myers Squibb press release
15 September 2015
New & experimental hepatitis C treatment

Ongoing Real World Study Reports High Sustained Viral Response Rates with VIEKIRAX® + EXVIERA® in Genotype 1 Hepatitis C Patients

Editor's pick
AbbVie press release
14 September 2015
New & experimental hepatitis C treatment

Hepatitis C patients in England denied lifesaving liver drug

Editor's pick
The Observer
18 August 2015
Access to healthcare

Medicines Patent Pool At 5 Years: Promises Kept, Changes Ahead – An Interview With Greg Perry

Editor's pick
Intellectual Property Watch
4 August 2015
New & experimental hepatitis C treatment

FDA OK’s BMS Daklinza (Daclatasvir) to Treat Hep C Genotype 3

Editor's pick
AIDSMeds
27 July 2015